Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDexCom Inc

DexCom Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
87.46 USD 4.49 ( 5.41%)
Last update at 2026-11-04T15:11:00Z
VOLUME
610727
Market Cap
24155.65M
P/E
30.99

Momentum Score

…

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
84.75
Low
88.32
High
52 Week Price Range
54.11
Low
89.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

DexCom makes continuous glucose monitoring systems and software for people with diabetes, earning recurring revenue from sensors and related services. Long-term growth drivers include rising diabetes prevalence, broader CGM adoption among Type 1 and insulin‑treated Type 2 patients, product integration with insulin delivery and digital platforms, and international reimbursement expansion; these trends may support revenue durability.
Key risks include intensifying competition (Abbott, Medtronic), reimbursement and regulatory changes, and execution or supply‑chain challenges as the company scales, which investors should monitor.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
82.97
Dividend Yield
-
Revenue TTM
4662.00M
Revenue Per Share
11.95
Gross Profit TTM
2801.90M
Debt / Equity
0.51
ROE
34.50%
Net Debt
472.00M
ROCE
21.72%
Diluted EPS TTM
2.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1088.40M 709.00M 710.40M 390.80M 173.90M
Net income 836.30M 576.20M 541.50M 341.20M 154.70M
Selling general administrative 1291.00M 1091.60M 1004.60M 1000.20M 810.50M
Selling and marketing expenses - 194.20M 180.80M - -
Gross profit 2801.90M 2438.20M 2288.90M 1883.10M 1680.50M
Reconciled depreciation 251.80M 217.70M 186.00M 155.90M 102.00M
Ebit 911.80M 728.00M 730.70M 391.20M 175.40M
Ebitda 1163.60M 945.70M 916.70M 416.90M 277.40M
Depreciation and amortization 251.80M 217.70M 186.00M 25.70M 102.00M
Non operating income net other - - - 18.00M -3.20M
Operating income 911.80M 600.00M 597.70M 391.20M 175.40M
Other operating expenses 3750.20M 3433.00M 3024.60M 2518.60M 2182.70M
Interest expense 18.30M 19.00M 20.30M 18.60M 102.00M
Tax provision 252.10M 132.80M 168.90M 49.60M 19.20M
Interest income 112.70M 134.20M 135.00M 18.00M -
Net interest income 94.40M 115.20M 114.70M -18.60M -100.30M
Income tax expense 252.10M 132.80M 168.90M 49.60M 19.20M
Total revenue 4662.00M 4033.00M 3622.30M 2909.80M 2448.50M
Total operating expenses 1890.10M 1838.20M 1691.20M 1491.90M 1414.70M
Cost of revenue 1860.10M 1594.80M 1333.40M 1026.70M 768.00M
Total other income expense net 176.60M 109.00M 112.70M -0.40M -1.50M
Net income from continuing ops 836.30M 576.20M 541.50M 341.20M 154.70M
Net income applicable to common shares - - - 341.20M 154.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6339.90M 6484.50M 6264.50M 5391.70M 4863.60M
Intangible assets 70.80M 103.40M 134.50M 173.30M 42.00M
Other current assets 115.60M 145.80M 49.30M 192.60M 81.60M
Total liab 3593.90M 4381.90M 4195.90M 3259.90M 2612.10M
Total stockholder equity 2746.00M 2102.60M 2068.60M 2131.80M 2251.50M
Other current liab 1768.90M 1309.50M 1240.10M 134.30M 125.20M
Common stock 0.40M 0.40M 0.40M 0.40M 0.10M
Capital stock 0.40M 0.40M 0.40M 0.40M 0.10M
Retained earnings 2433.90M 1597.60M 1021.40M 479.90M -47.40M
Other liab - - - 68.70M 90.00M
Good will 24.20M 22.80M 25.20M 25.70M 26.50M
Other assets - - - 369.30M 220.80M
Cash 917.70M 606.10M 566.30M 642.30M 1052.60M
Total current liabilities 2142.50M 2932.00M 1556.00M 1839.30M 720.80M
Current deferred revenue 7.70M 8.00M 18.40M 10.10M 2.10M
Net debt 472.00M 1981.30M 2027.70M 1443.10M 769.20M
Short term debt 21.60M 1226.90M 21.10M 793.10M 20.50M
Short long term debt - 1204.40M - 772.60M -
Short long term debt total 1389.70M 2587.40M 2594.00M 2085.40M 1821.80M
Other stockholder equity 196.70M 512.60M 1063.50M 1663.10M 2298.30M
Property plant equipment - - - 1135.60M 889.90M
Total current assets 4033.30M 4301.40M 4425.90M 3668.80M 3684.40M
Long term investments 218.00M 119.30M 38.50M - -
Net tangible assets - - - 2131.80M 2183.00M
Short term investments 1081.00M 1973.30M 2157.80M 1813.90M 1678.60M
Net receivables 1289.90M 1033.60M 987.50M 713.30M 514.30M
Long term debt 1240.90M 1237.00M 2434.20M 1197.70M 1702.70M
Inventory 629.10M 542.60M 559.60M 306.70M 357.30M
Accounts payable 344.30M 345.30M 276.40M 901.80M 573.00M
Accumulated other comprehensive income 115.00M -8.00M -16.70M -11.60M 0.50M
Common stock total equity - - - 0.40M 0.10M
Retained earnings total equity - - - 479.90M -47.40M
Treasury stock - - - - -206.20M
Non currrent assets other 60.70M 53.70M 36.50M 47.10M 2.00M
Non current assets total 2306.60M 2183.10M 1838.60M 1722.90M 1179.20M
Capital lease obligations 148.80M 146.00M 159.80M 174.70M 119.10M
Long term debt total - - - 1197.70M 1702.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 898.90M -207.50M -1116.20M -138.50M 193.20M
Change to liabilities - - - 303.60M 68.40M
Total cashflows from investing activities 536.00M -207.50M - -521.50M -216.10M
Net borrowings -1207.50M 0.00M - - -
Total cash from financing activities -1686.40M -734.80M -318.60M -552.50M 10.40M
Change to operating activities - - - -128.90M -11.00M
Net income 836.30M 576.20M 541.50M 341.20M 154.70M
Change in cash 311.80M 39.80M -75.80M -410.30M 235.40M
Begin period cash flow 607.30M 567.50M 643.30M 1053.60M 818.20M
End period cash flow 919.10M 607.30M 567.50M 643.30M 1053.60M
Total cash from operating activities 1440.70M 989.50M 748.50M 669.50M 442.50M
Issuance of capital stock 28.10M 28.20M 26.60M 22.50M 20.30M
Depreciation 251.80M 217.70M 186.00M 155.90M 102.00M
Other cashflows from investing activities 0.60M -15.50M - -18.20M -20.10M
Dividends paid - - 1230.60M - -
Change to inventory -63.70M 12.40M -252.60M 49.30M -112.20M
Change to account receivables -201.90M -35.00M -260.10M -199.90M -75.50M
Sale purchase of stock -500.00M -750.00M -688.70M -557.70M 20.30M
Other cashflows from financing activities -7.00M -13.00M -99.80M -17.30M -9.90M
Change to netincome - - - 145.90M 242.30M
Capital expenditures 363.50M 358.80M 236.60M 364.80M 389.20M
Change receivables - - - -199.90M -75.50M
Cash flows other operating - - - -126.50M 62.80M
Cash and cash equivalents changes - - - -404.50M 236.80M
Change in working capital 103.40M 108.80M 3.20M 27.70M -132.00M
Stock based compensation 159.60M 170.40M 150.80M 126.50M 113.40M
Other non cash items -92.60M -39.80M -78.00M 39.80M 209.30M
Free cash flow 1077.20M 630.70M 511.90M 304.70M 53.30M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DXCM
DexCom Inc		 4.49
5.41%		 87.46 30.99 25.91 5.18 9.08 5.22 17.91
ABT
Abbott Laboratories		 3.15
2.88%		 112.55 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 4.05
4.10%		 102.93 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 18.89
6.08%		 329.44 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 48.37 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

6340 Sequence Drive, San Diego, CA, United States, 92121

858 200 0200

https://www.dexcom.com

11000

Name Title Year Born
Mr. Kevin Ronald Sayer Exec. Chairman, CEO & Pres 1958
Mr. Jereme M. Sylvain Exec. VP, CFO & Chief Accounting Officer 1980
Mr. Jacob Steven Leach Exec. VP & COO 1978
Mr. Paul R. Flynn Exec. VP of Global Revenue 1969
Mr. Sean Christensen Director of Corp. Affairs & Head of Investor Relations NA
Mr. Michael Brown Exec. VP & Chief Legal Officer 1970
Mr. Matthew Dolan Exec. VP of Strategy, Corp. Devel. & Dexcom Labs 1981
Ms. Sadie M. Stern Exec. VP & Chief HR Officer 1975
Mr. Andrew K. Balo Exec. VP of Global Medical Affairs, Access & Evidence 1948
Mr. Steven R. Pacelli Exec. VP & MD of Dexcom Ventures 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…